Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2021–2024

Bio2Brain · Nose-to-Brain Delivery of Biopharmaceutics for the therapy of central nervous system diseases: A design-based approach for efficient drug delivery systems

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2021-01-01 → 2024-12-31
EU contribution
€3,493,710
Participants
9
Scheme
MSCA-ITN

Lines connect the coordinator with its partners.

Results in brief

Nose-to-Brain Delivery of Biopharmaceutics for the therapy of central nervous system diseases: A design-based approach for efficient drug delivery systems

The Bio2Brain network has successfully achieved its aim of developing a comprehensive research and training program designed to train young scientists in innovating novel technologies for the efficient delivery of biopharmaceuticals from the nose to the brain. This initiative provided a unique opportunity for 16 early-career researchers to establish new paradigms and treatments for neurological diseases. Bio2Brain has laid the groundwork for the future transfer of the developed technologies, paving the way for clinical development and GMP manufacturing. Central nervous system (CNS) disorders and spinal cord diseases affect approximately 165 million Europeans, with conditions such as Multiple Sclerosis, Alzheimer’s disease, and Parkinson’s disease. These disorders are often associated with high morbidity, significant side effects, severe suffering for patients and their families, and a substantial burden on social systems. To address these challenges, 18 project partners from both academia and industry have collaborated to create the trans-European research network Bio2Brain, focusing on investigating efficient administration routes for biopharmaceuticals aimed at treating CNS disorders. The Bio2Brain network successfully combined expertise in chemistry, biology, neurology, physics, pharmacy, clinical and translational neuroscience, computational modelling, regulatory affairs, and nano- and biotechnology. This trans-European research network offered an exceptional training and collaborative environment for the interdisciplinary and intersectoral development of the 16 early-stage Researchers (ESRs).

Data: CORDIS, © European Union

Project objective

Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around 165 million Europeans with disorders such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. CNS disorders are often connected with high morbidity, significant side effects, suffering of the patients and their families, as well as an enormous burden on the welfare systems. Therefore, in terms of social sustainability, Bio2Brain contributes to increased benefit for both, the society as whole and particularly for those individuals at a disadvantage through these disorders. A highly critical challenge of CNS diseases is the low central availability drugs in general and in particular of biopharmaceuticals like monoclonal antibodies (mAbs). Hence, approved medicinal products with a low CNS bioavailability are currently delivered via intrathecal, intracerebroventricular or intraparenchymal injections. In this way, they are delivered directly to the CNS. Unfortunately, such delivery systems are invasive, require a surgery with high risks, have a low patient compliance and are poorly controllable. Therefore, there is a critical need for a more safe and effective new approach, that means a paradigm shift, for drug delivery technologies in the treatment of CNS diseases. The Bio2Brain network will create a research environment for the interdisciplinary and intersectorial training of 13 ESRs supported by 11 academic teams (beneficiaries and partner universities), 6 key industrial stakeholders and an academic non-profit organization. As an important benefit, the close and frequent exposure of the ESRs to the private sector and to key technologies will significantly enhance their employability.

Original text from CORDIS.

Participants

  • FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV · MunchenCoordinatorGermany
  • CONTIPRO AS · DOLNI DOBROUCCzechia
  • ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS · THERMI THESSALONIKIGreece
  • HOCHSCHULE BIBERACH · BiberachGermany
  • LABORATORIO EUROPEO DI SPETTROSCOPIE NON LINEARI · Sesto-Fiorentino (Fi)Italy
  • MYBIOTECH GMBH · UberherrnGermany
  • QUEEN MARY UNIVERSITY OF LONDON · LONDONUnited Kingdom
  • THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGEUnited Kingdom
  • UNIVERSITAET BERN · BernSwitzerland

Links

Data: CORDIS, © European Union